O-linked glycosylation modifies CD44 adhesion to hyaluronate in colon carcinoma cells

被引:37
作者
Dasgupta, A
Takahashi, K
Cutler, M
Tanabe, KK
机构
[1] MASSACHUSETTS GEN HOSP,DIV SURG ONCOL,BOSTON,MA 02114
[2] MASSACHUSETTS GEN HOSP,DIV MED ONCOL,BOSTON,MA 02114
[3] HARVARD UNIV,SCH MED,BOSTON,MA 02114
关键词
D O I
10.1006/bbrc.1996.1475
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CD44 alternative splicing patterns differ between normal and malignant tissue, and accordingly, modulation of CD44 splicing has received the most attention in studies that have examined the role of CD44 in tumor progression. Many investigators have examined functional differences between individual CD44 alternative splice variants. However, specific CD44 isoforms function uniquely depending on the type of cell on which they are expressed, thereby suggesting that additional tissue-specific mechanisms regulate CD44 function. To the present study we have demonstrated that colon carcinoma cells modify CD44 with O-linked glycosyl groups, and blockade of this glycosylation enhances their CD44-mediated adhesion to hyaluronate. This enhancement is attributable principally to CD44H (CD44s) rather than high molecular weight CD44 variants. Use of site-directed mutant CD44H cDNA transfectants demonstrated that CD44 O-linked glycosylation modulates interaction between hyaluronate and the B loop domain of CD44. The influence of glycosylation on CD44 function in colon carcinoma cells is specific to the presence of O-linked sugars; inhibition of N-linked glycosylation had minimal influence on CDU function. These findings indicate that O-linked glycosylation may be as important as alternative splicing in the regulation of CD44 function and the broad spectrum of biological processes attributed to it, including normal development, tumor metastases, and lymphocyte function. (C) 1996 Academic Press, Inc.
引用
收藏
页码:110 / 117
页数:8
相关论文
共 40 条
[11]  
FOX SB, 1994, CANCER RES, V54, P4539
[12]  
GANSAUGE F, 1995, CANCER RES, V55, P5499
[13]   A NEW VARIANT OF GLYCOPROTEIN CD44 CONFERS METASTATIC POTENTIAL TO RAT CARCINOMA-CELLS [J].
GUNTHERT, U ;
HOFMANN, M ;
RUDY, W ;
REBER, S ;
ZOLLER, M ;
HAUSSMANN, I ;
MATZKU, S ;
WENZEL, A ;
PONTA, H ;
HERRLICH, P .
CELL, 1991, 65 (01) :13-24
[14]  
HEIDER KH, 1993, CANCER RES, V53, P4197
[15]  
HUET S, 1989, J IMMUNOL, V143, P798
[16]   PROTEOGLYCAN FORMS OF THE LYMPHOCYTE HOMING RECEPTOR CD44 ARE ALTERNATIVELY SPLICED VARIANTS CONTAINING THE V3 EXON [J].
JACKSON, DG ;
BELL, JI ;
DICKINSON, R ;
TIMANS, J ;
SHIELDS, J ;
WHITTLE, N .
JOURNAL OF CELL BIOLOGY, 1995, 128 (04) :673-685
[17]   LYMPHOCYTE HOMING AND CLINICAL BEHAVIOR OF NON-HODGKINS-LYMPHOMA [J].
JALKANEN, S ;
JOENSUU, H ;
SODERSTROM, KO ;
KLEMI, P .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (05) :1835-1840
[18]   GLYCOSYLATION OF CD44 NEGATIVELY REGULATES ITS RECOGNITION OF HYALURONAN [J].
KATOH, S ;
ZHENG, Z ;
ORITANI, K ;
SHIMOZATO, T ;
KINCADE, PW .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (02) :419-429
[19]   CD44 VARIANT EXON EPITOPES IN PRIMARY BREAST-CANCER AND LENGTH OF SURVIVAL [J].
KAUFMANN, M ;
HEIDER, KH ;
SINN, HP ;
VONMINCKWITZ, G ;
PONTA, H ;
HERRLICH, P .
LANCET, 1995, 345 (8950) :615-619
[20]  
KUAN SF, 1989, J BIOL CHEM, V264, P19271